interferon beta-1b 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5140 145155-23-3

Description:

MoleculeDescription

Synonyms:

  • interferon beta-1b
  • betaseron
A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS. A possible role for IFNs in prophylaxis or early treatment of COVID-19 has been suggested to compensate for possibly insufficient endogenous IFN production. However, the efficacy and safety of IFNs for treatment or prevention of COVID-19 were not established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
4 MU P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 30, 1995 EMA Bayer AG
July 23, 1993 FDA BAYER HEALTHCARE PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1349.91 15.16 558 24461 47920 63416083
Influenza like illness 1053.40 15.16 517 24502 66307 63397696
Injection site erythema 991.26 15.16 533 24486 82641 63381362
Injection site pain 826.91 15.16 556 24463 129244 63334759
Injection site reaction 575.72 15.16 331 24688 58193 63405810
Injection site mass 532.57 15.16 219 24800 18437 63445566
Injection site bruising 422.53 15.16 241 24778 41669 63422334
Multiple sclerosis 311.46 15.16 164 24855 24208 63439795
Chills 281.52 15.16 281 24738 113097 63350906
Injection site induration 248.61 15.16 104 24915 9122 63454881
Injection site rash 244.37 15.16 128 24891 18681 63445322
Injection site scar 235.94 15.16 59 24960 959 63463044
Injection site necrosis 214.97 15.16 58 24961 1286 63462717
Gait disturbance 194.89 15.16 296 24723 182882 63281121
Hypoaesthesia 176.10 15.16 270 24749 168123 63295880
Injection site atrophy 172.93 15.16 42 24977 601 63463402
Depression 169.96 15.16 289 24730 196203 63267800
Injection site abscess 151.52 15.16 43 24976 1155 63462848
Injection site cellulitis 149.57 15.16 43 24976 1211 63462792
Product dose omission issue 149.09 15.16 302 24717 234011 63229992
Off label use 133.19 15.16 50 24969 674412 62789591
Injection site ulcer 130.34 15.16 33 24986 565 63463438
Injection site infection 127.00 15.16 42 24977 1901 63462102
Injection site discolouration 124.05 15.16 61 24958 7787 63456216
Muscular weakness 121.94 15.16 192 24827 122161 63341842
Balance disorder 121.74 15.16 158 24861 84264 63379739
Optic neuritis 111.22 15.16 58 24961 8377 63455626
Gait inability 110.97 15.16 120 24899 52839 63411164
Injection site haematoma 110.67 15.16 54 24965 6778 63457225
Injection site swelling 96.54 15.16 106 24913 47466 63416537
Central nervous system lesion 93.42 15.16 56 24963 10579 63453424
Injection site inflammation 92.50 15.16 40 24979 3803 63460200
Injection site urticaria 79.09 15.16 56 24963 14017 63449986
Depressed mood 78.86 15.16 88 24931 40103 63423900
Toxicity to various agents 72.16 15.16 7 25012 247243 63216760
Joint swelling 68.42 15.16 22 24997 327644 63136359
Abdominal discomfort 66.20 15.16 22 24997 320863 63143140
Rheumatoid arthritis 64.90 15.16 11 25008 253808 63210195
Injection site calcification 62.83 15.16 11 25008 23 63463980
Acute kidney injury 59.95 15.16 15 25004 263400 63200603
Tremor 59.83 15.16 149 24870 132090 63331913
Seizure 59.55 15.16 149 24870 132485 63331518
Diarrhoea 58.24 15.16 122 24897 715244 62748759
Coordination abnormal 57.77 15.16 46 24973 13727 63450276
Feeling cold 56.92 15.16 58 24961 23830 63440173
Arthropathy 56.14 15.16 12 25007 234780 63229223
Glossodynia 55.10 15.16 4 25015 178872 63285131
Pyrexia 53.92 15.16 343 24676 470135 62993868
Memory impairment 53.10 15.16 123 24896 104135 63359868
Injection site pruritus 52.25 15.16 76 24943 45040 63418963
Hemianaesthesia 49.15 15.16 14 25005 381 63463622
Fall 48.66 15.16 292 24727 392042 63071961
Drug interaction 48.48 15.16 15 25004 229116 63234887
Injection site irritation 48.41 15.16 28 24991 4950 63459053
Paraparesis 46.37 15.16 21 24998 2227 63461776
Completed suicide 45.61 15.16 3 25016 145670 63318333
Progressive multiple sclerosis 44.68 15.16 17 25002 1161 63462842
Therapeutic product effect decreased 43.93 15.16 11 25008 193176 63270827
Injection site haemorrhage 43.89 15.16 51 24968 24263 63439740
Injection site scab 43.48 15.16 13 25006 421 63463582
Wound 41.88 15.16 7 25012 163256 63300747
Lower respiratory tract infection 40.62 15.16 3 25016 132304 63331699
Muscle spasms 39.25 15.16 143 24876 156007 63307996
Decreased interest 39.00 15.16 21 24998 3233 63460770
Systemic lupus erythematosus 38.60 15.16 17 25002 208901 63255102
Paraesthesia 37.99 15.16 142 24877 156824 63307179
Condition aggravated 37.56 15.16 63 24956 402154 63061849
Rash 36.66 15.16 107 24912 560764 62903239
Drug ineffective 36.52 15.16 252 24767 1044513 62419490
Drug intolerance 36.18 15.16 41 24978 308620 63155383
Neutralising antibodies positive 35.73 15.16 10 25009 255 63463748
Urinary incontinence 35.72 15.16 53 24966 31961 63432042
Febrile neutropenia 35.48 15.16 3 25016 118446 63345557
Pain in extremity 35.04 15.16 237 24782 331249 63132754
Headache 34.99 15.16 392 24627 632849 62831154
Hypotension 34.42 15.16 34 24985 272570 63191433
Neutropenia 34.33 15.16 13 25006 174992 63289011
Limb discomfort 34.32 15.16 50 24969 29666 63434337
Sensory disturbance 34.04 15.16 34 24985 13638 63450365
Treatment failure 34.02 15.16 18 25001 199025 63264978
Mobility decreased 33.93 15.16 115 24904 121044 63342959
Peroneal nerve palsy 33.73 15.16 22 24997 4813 63459190
Stomatitis 33.33 15.16 7 25012 138718 63325285
Hyponatraemia 33.07 15.16 3 25016 111897 63352106
Therapeutic product effect incomplete 32.88 15.16 5 25014 125051 63338952
Muscle spasticity 31.70 15.16 41 24978 21753 63442250
Anti-interferon antibody positive 31.59 15.16 6 25013 23 63463980
Expanded disability status scale score increased 31.55 15.16 11 25008 585 63463418
Breast cancer female 30.64 15.16 32 24987 13527 63450476
Asthenia 30.25 15.16 256 24763 383348 63080655
Feeling abnormal 30.07 15.16 127 24892 148265 63315738
Intentional product use issue 29.62 15.16 7 25012 127885 63336118
Infection 28.44 15.16 29 24990 229144 63234859
Secondary progressive multiple sclerosis 28.39 15.16 13 25006 1414 63462589
Blister 28.35 15.16 8 25011 129806 63334197
Peripheral swelling 28.34 15.16 38 24981 265904 63198099
Burning sensation 27.47 15.16 64 24955 54343 63409660
Visual impairment 27.11 15.16 84 24935 84362 63379641
Wheezing 27.10 15.16 3 25016 95592 63368411
Device leakage 26.18 15.16 22 24997 7074 63456929
Fatigue 25.98 15.16 492 24527 887536 62576467
Dyspnoea 25.82 15.16 154 24865 661159 62802844
Swelling 25.80 15.16 43 24976 275335 63188668
Psoriatic arthropathy 25.63 15.16 3 25016 91517 63372486
Decreased appetite 25.62 15.16 37 24982 251015 63212988
Alopecia 25.35 15.16 60 24959 337476 63126527
Injection site erosion 25.09 15.16 6 25013 80 63463923
Trigeminal neuralgia 24.52 15.16 16 25003 3503 63460500
Pneumonia 24.43 15.16 95 24924 456672 63007331
Migraine 23.75 15.16 92 24927 103254 63360749
Injection site nerve damage 23.57 15.16 5 25014 37 63463966
Drug hypersensitivity 23.51 15.16 55 24964 310632 63153371
Overdose 23.50 15.16 8 25011 115070 63348933
Arthralgia 23.11 15.16 131 24888 569579 62894424
Seizure like phenomena 22.01 15.16 10 25009 1069 63462934
Hypokalaemia 21.57 15.16 7 25012 103797 63360206
Anaemia 21.36 15.16 53 24966 293377 63170626
Urinary tract infection 21.02 15.16 177 24842 264507 63199496
Discomfort 20.96 15.16 21 24998 167353 63296650
Loss of consciousness 20.82 15.16 97 24922 118024 63345979
Speech disorder 20.73 15.16 48 24971 40581 63423422
Injection site fibrosis 20.37 15.16 4 25015 19 63463984
Blood creatinine increased 19.96 15.16 5 25014 87839 63376164
Sinusitis 19.77 15.16 37 24982 226616 63237387
Fat necrosis 19.67 15.16 8 25011 652 63463351
Injection site injury 19.60 15.16 8 25011 658 63463345
Magnetic resonance imaging abnormal 19.02 15.16 13 25006 3072 63460931
Thrombocytopenia 18.89 15.16 19 25000 151138 63312865
Osteoarthritis 18.83 15.16 7 25012 95336 63368667
Lack of injection site rotation 18.82 15.16 7 25012 449 63463554
Demyelination 18.70 15.16 18 25001 6902 63457101
Injection site nodule 18.68 15.16 14 25005 3821 63460182
C-reactive protein increased 18.62 15.16 7 25012 94700 63369303
Diplegia 18.60 15.16 9 25010 1108 63462895
Hemiparesis 18.43 15.16 33 24986 23249 63440754
COVID-19 18.20 15.16 11 25008 113092 63350911
Irritable bowel syndrome 18.14 15.16 5 25014 82407 63381596
Needle fatigue 18.03 15.16 5 25014 123 63463880
Neutralising antibodies 17.27 15.16 4 25015 46 63463957
Lipoatrophy 17.25 15.16 6 25013 317 63463686
Decubitus ulcer 17.22 15.16 21 24998 10499 63453504
Quadriplegia 17.17 15.16 10 25009 1790 63462213
Scar 17.10 15.16 24 24995 13758 63450245
Micturition urgency 17.07 15.16 20 24999 9591 63454412
Thyroid function test abnormal 17.07 15.16 13 25006 3634 63460369
Skin mass 17.06 15.16 16 25003 5939 63458064
Motor dysfunction 16.84 15.16 21 24998 10740 63453263
Ataxia 16.72 15.16 25 24994 15170 63448833
Bladder disorder 16.54 15.16 19 25000 8927 63455076
Oedema 16.41 15.16 9 25010 97613 63366390
Accident at home 16.27 15.16 5 25014 178 63463825
Hypersensitivity 16.19 15.16 60 24959 292625 63171378
Ill-defined disorder 16.15 15.16 6 25013 81749 63382254
Feeling hot 16.07 15.16 50 24969 50304 63413699
Hospitalisation 15.83 15.16 71 24948 85010 63378993
Head injury 15.81 15.16 34 24985 27362 63436641
Central nervous system inflammation 15.81 15.16 5 25014 196 63463807
Product prescribing issue 15.76 15.16 11 25008 2688 63461315
Diplopia 15.52 15.16 31 24988 23697 63440306
Skin necrosis 15.42 15.16 23 24996 13927 63450076
Injection site abscess sterile 15.32 15.16 3 25016 14 63463989

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 522.81 23.30 166 6998 12967 34936800
Influenza like illness 450.42 23.30 180 6984 27454 34922313
Injection site pain 338.15 23.30 163 7001 38842 34910925
Injection site erythema 249.75 23.30 101 7063 15798 34933969
Injection site reaction 164.90 23.30 71 7093 12962 34936805
Injection site mass 153.85 23.30 56 7108 6570 34943197
Multiple sclerosis 142.61 23.30 53 7111 6592 34943175
Chills 122.87 23.30 114 7050 80929 34868838
Gait disturbance 121.88 23.30 116 7048 85024 34864743
Injection site cellulitis 119.62 23.30 27 7137 554 34949213
Injection site infection 109.23 23.30 28 7136 998 34948769
Injection site induration 80.90 23.30 28 7136 2832 34946935
Injection site abscess 79.86 23.30 21 7143 828 34948939
Depression 76.97 23.30 97 7067 97001 34852766
Hypoaesthesia 75.31 23.30 77 7087 61367 34888400
Gait inability 72.71 23.30 48 7116 20710 34929057
Injection site scar 71.99 23.30 16 7148 305 34949462
Injection site rash 63.80 23.30 26 7138 4127 34945640
Balance disorder 59.19 23.30 56 7108 40598 34909169
Expanded disability status scale score increased 55.17 23.30 13 7151 324 34949443
Muscular weakness 51.72 23.30 69 7095 72828 34876939
Injection site inflammation 50.88 23.30 15 7149 903 34948864
Mobility decreased 46.72 23.30 43 7121 30085 34919682
Injection site swelling 46.13 23.30 29 7135 11498 34938269
Injection site bruising 45.60 23.30 26 7138 8637 34941130
Muscle spasticity 43.11 23.30 22 7142 5866 34943901
Injection site necrosis 41.92 23.30 11 7153 430 34949337
Depressed mood 41.00 23.30 33 7131 19284 34930483
Optic neuritis 40.39 23.30 18 7146 3556 34946211
Myopathy toxic 38.82 23.30 11 7153 575 34949192
Injection site discolouration 32.35 23.30 12 7152 1481 34948286
Muscle spasms 31.89 23.30 56 7108 74945 34874822
Headache 31.14 23.30 101 7063 200534 34749233
Acute kidney injury 30.88 23.30 12 7152 304976 34644791
Injection site haematoma 30.26 23.30 12 7152 1773 34947994
Muscle disorder 28.97 23.30 13 7151 2608 34947159
Secondary progressive multiple sclerosis 28.87 23.30 8 7156 385 34949382
Product dose omission issue 28.07 23.30 70 7094 119641 34830126
Hemianaesthesia 27.92 23.30 6 7158 97 34949670
Visual impairment 27.07 23.30 35 7129 35767 34914000
Skin necrosis 26.67 23.30 16 7148 5837 34943930
Tremor 25.67 23.30 54 7110 82533 34867234
Injection site atrophy 25.22 23.30 5 7159 53 34949714
Bronchopulmonary aspergillosis 24.83 23.30 22 7142 14637 34935130
Pain 24.81 23.30 95 7069 204580 34745187
Vision blurred 24.48 23.30 38 7126 45925 34903842
Drug interaction 24.36 23.30 8 7156 225938 34723829
Hepatitis toxic 24.19 23.30 11 7153 2276 34947491
Decreased interest 23.86 23.30 11 7153 2349 34947418
Toxicity to various agents 23.61 23.30 6 7158 200356 34749411

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1446.04 14.69 551 25596 45982 79672259
Influenza like illness 1041.09 14.69 495 25652 71212 79647029
Injection site erythema 920.63 14.69 468 25679 77729 79640512
Injection site pain 899.68 14.69 548 25599 129290 79588951
Injection site reaction 522.12 14.69 285 25862 54500 79663741
Injection site mass 468.64 14.69 194 25953 19990 79698251
Multiple sclerosis 369.67 14.69 169 25978 22113 79696128
Injection site bruising 345.97 14.69 197 25950 40805 79677436
Chills 297.65 14.69 312 25835 159922 79558319
Injection site cellulitis 255.38 14.69 67 26080 1611 79716630
Injection site induration 253.89 14.69 102 26045 9717 79708524
Injection site rash 241.89 14.69 118 26029 17836 79700405
Gait disturbance 236.95 14.69 315 25832 207191 79511050
Injection site necrosis 215.29 14.69 57 26090 1421 79716820
Injection site scar 210.81 14.69 50 26097 783 79717458
Hypoaesthesia 199.66 14.69 269 25878 179083 79539158
Injection site infection 196.92 14.69 58 26089 2154 79716087
Injection site abscess 195.50 14.69 54 26093 1586 79716655
Depression 195.44 14.69 294 25853 216496 79501745
Injection site atrophy 175.64 14.69 38 26109 383 79717858
Gait inability 170.95 14.69 147 26000 58770 79659471
Product dose omission issue 169.04 14.69 296 25851 247241 79471000
Balance disorder 147.84 14.69 172 25975 98685 79619556
Muscular weakness 130.73 14.69 208 25939 160521 79557720
Injection site haematoma 120.83 14.69 49 26098 4778 79713463
Injection site discolouration 120.74 14.69 56 26091 7558 79710683
Injection site swelling 115.66 14.69 107 26040 47025 79671216
Injection site ulcer 110.81 14.69 29 26118 690 79717551
Injection site inflammation 108.67 14.69 43 26104 3933 79714308
Optic neuritis 105.97 14.69 55 26092 9465 79708776
Acute kidney injury 99.69 14.69 24 26123 519380 79198861
Toxicity to various agents 99.69 14.69 11 26136 421529 79296712
Depressed mood 90.86 14.69 95 26052 48385 79669856
Drug interaction 78.03 14.69 20 26127 415163 79303078
Mobility decreased 72.93 14.69 138 26009 122037 79596204
Off label use 69.14 14.69 120 26027 907095 78811146
Completed suicide 67.83 14.69 3 26144 245764 79472477
Tremor 67.82 14.69 163 25984 169920 79548321
Coordination abnormal 62.33 14.69 49 26098 17263 79700978
Fall 58.96 14.69 315 25832 487314 79230927
Muscle spasms 58.75 14.69 157 25990 174573 79543668
Hemianaesthesia 58.11 14.69 16 26131 464 79717777
Central nervous system lesion 57.33 14.69 42 26105 13326 79704915
Progressive multiple sclerosis 54.81 14.69 19 26128 1198 79717043
Febrile neutropenia 54.62 14.69 6 26141 230993 79487248
Hypotension 54.54 14.69 39 26108 440278 79277963
Headache 54.19 14.69 383 25764 653389 79064852
Diarrhoea 53.87 14.69 132 26015 880357 78837884
Muscle spasticity 53.14 14.69 49 26098 21426 79696815
Neutropenia 51.87 14.69 15 26132 287695 79430546
Injection site calcification 51.26 14.69 9 26138 25 79718216
Drug ineffective 51.02 14.69 183 25964 1080730 78637511
Pyrexia 50.76 14.69 388 25759 678321 79039920
Pain in extremity 49.95 14.69 244 25903 364294 79353947
Feeling cold 49.75 14.69 54 26093 28675 79689566
Secondary progressive multiple sclerosis 48.54 14.69 18 26129 1379 79716862
Injection site irritation 48.31 14.69 24 26123 3766 79714475
Injection site urticaria 47.68 14.69 37 26110 12789 79705452
Memory impairment 46.58 14.69 109 26038 111625 79606616
Paraparesis 45.30 14.69 23 26124 3780 79714461
Expanded disability status scale score increased 44.57 14.69 14 26133 647 79717594
Paraesthesia 41.76 14.69 140 26007 176183 79542058
Injection site haemorrhage 40.79 14.69 48 26099 27822 79690419
Joint swelling 40.64 14.69 22 26125 288624 79429617
Sensory disturbance 40.44 14.69 36 26111 15041 79703200
Urinary incontinence 40.37 14.69 58 26089 40851 79677390
Decreased interest 40.11 14.69 21 26126 3676 79714565
Seizure 39.59 14.69 144 26003 188690 79529551
Thrombocytopenia 39.16 14.69 19 26128 265240 79453001
Injection site pruritus 38.91 14.69 58 26089 42225 79676016
Injection site scab 38.73 14.69 11 26136 358 79717883
Hyponatraemia 38.72 14.69 6 26141 177842 79540399
Overdose 38.37 14.69 7 26140 184199 79534042
Rheumatoid arthritis 37.32 14.69 11 26136 208459 79509782
Visual impairment 36.36 14.69 88 26059 92043 79626198
Pain 35.82 14.69 370 25777 703432 79014809
Migraine 34.99 14.69 84 26063 87409 79630832
Urinary tract infection 34.91 14.69 180 25967 274332 79443909
Asthenia 34.05 14.69 285 25862 511404 79206837
Breast cancer female 34.03 14.69 29 26118 11432 79706809
Limb discomfort 33.04 14.69 47 26100 32803 79685438
Magnetic resonance imaging abnormal 32.90 14.69 18 26129 3441 79714800
Fatigue 32.51 14.69 455 25692 929272 78788969
Rash 32.01 14.69 91 26056 578267 79139974
Muscle tightness 31.04 14.69 29 26118 12885 79705356
Vision blurred 30.50 14.69 90 26057 105808 79612433
Abdominal discomfort 29.98 14.69 23 26124 250704 79467537
Anti-interferon antibody positive 29.30 14.69 5 26142 11 79718230
Anaemia 29.30 14.69 64 26083 444951 79273290
Hemiparesis 29.23 14.69 45 26102 33688 79684553
Pancytopenia 29.20 14.69 9 26138 165736 79552505
Intentional product use issue 29.17 14.69 7 26140 152105 79566136
Lower respiratory tract infection 28.96 14.69 4 26143 129216 79589025
Feeling abnormal 28.91 14.69 116 26031 159083 79559158
Injection site nodule 28.76 14.69 17 26130 3763 79714478
General physical health deterioration 28.40 14.69 29 26118 275209 79443032
Therapeutic product effect incomplete 28.20 14.69 6 26141 141639 79576602
Skin necrosis 27.88 14.69 32 26115 18055 79700186
Stomatitis 27.66 14.69 7 26140 146750 79571491
Neutralising antibodies positive 27.53 14.69 8 26139 283 79717958
Injection site injury 27.21 14.69 10 26137 747 79717494
Arthropathy 27.19 14.69 12 26135 177099 79541142
Treatment failure 27.06 14.69 11 26136 170475 79547766
Therapeutic product effect decreased 26.95 14.69 10 26137 163853 79554388
Band sensation 26.82 14.69 10 26137 778 79717463
Pneumonia 26.46 14.69 119 26028 660127 79058114
Speech disorder 25.90 14.69 56 26091 54389 79663852
Dyspnoea 25.30 14.69 171 25976 856854 78861387
Burning sensation 25.30 14.69 58 26089 58574 79659667
Drug intolerance 24.86 14.69 30 26117 264089 79454152
Malignant neoplasm progression 24.66 14.69 7 26140 135983 79582258
Intentional overdose 24.41 14.69 3 26144 105957 79612284
Motor dysfunction 24.30 14.69 27 26120 14706 79703535
Trigeminal neuralgia 24.28 14.69 15 26132 3594 79714647
Condition aggravated 24.08 14.69 84 26063 501040 79217201
Bronchopulmonary aspergillosis 24.06 14.69 33 26114 22261 79695980
Oedema 23.93 14.69 5 26142 119575 79598666
Renal impairment 23.74 14.69 11 26136 157772 79560469
Loss of consciousness 23.36 14.69 113 26034 167830 79550411
Panniculitis lobular 23.33 14.69 5 26142 48 79718193
Injection site fibrosis 23.09 14.69 4 26143 10 79718231
Blood creatinine increased 23.03 14.69 11 26136 155046 79563195
Fat necrosis 22.42 14.69 9 26138 854 79717387
Injection site nerve damage 21.53 14.69 5 26142 71 79718170
Diplopia 21.45 14.69 39 26108 33427 79684814
Decubitus ulcer 21.28 14.69 26 26121 15661 79702580
Wheezing 21.16 14.69 6 26141 116658 79601583
C-reactive protein increased 21.01 14.69 8 26139 129019 79589222
Neuromyelitis optica spectrum disorder 20.78 14.69 9 26138 1033 79717208
Musculoskeletal disorder 20.56 14.69 30 26117 21418 79696823
Myopathy toxic 20.33 14.69 9 26138 1089 79717152
Bradycardia 19.55 14.69 10 26137 135547 79582694
COVID-19 19.44 14.69 14 26133 157660 79560581
Peroneal nerve palsy 19.41 14.69 16 26131 6026 79712215
Glossodynia 19.33 14.69 5 26142 103332 79614909
Demyelination 19.25 14.69 18 26129 8005 79710236
Connective tissue inflammation 18.99 14.69 3 26144 3 79718238
Weight increased 18.98 14.69 39 26108 277347 79440894
Diplegia 18.88 14.69 10 26137 1793 79716448
Hypoglycaemia 18.84 14.69 5 26142 101589 79616652
Decreased appetite 18.81 14.69 54 26093 342364 79375877
Lack of injection site rotation 18.79 14.69 7 26140 543 79717698
Neutrophil count decreased 18.66 14.69 4 26143 93955 79624286
Thyroid function test abnormal 18.52 14.69 12 26135 3122 79715119
Progressive relapsing multiple sclerosis 18.52 14.69 4 26143 40 79718201
Injection site erosion 18.43 14.69 5 26142 137 79718104
Ataxia 18.41 14.69 31 26116 25008 79693233
Interstitial lung disease 18.30 14.69 7 26140 112593 79605648
Skin warm 18.11 14.69 16 26131 6616 79711625
Rhabdomyolysis 17.46 14.69 6 26141 103125 79615116
Product use in unapproved indication 17.30 14.69 35 26112 250324 79467917
Micturition urgency 17.23 14.69 21 26126 12620 79705621
Accident at home 17.20 14.69 5 26142 177 79718064
Scar 17.17 14.69 23 26124 15173 79703068
Hospitalisation 16.56 14.69 68 26079 94168 79624073
Feeling hot 16.46 14.69 50 26097 59684 79658557
Hypokalaemia 16.23 14.69 14 26133 144026 79574215
Head injury 16.16 14.69 37 26110 37332 79680909
Psoriatic arthropathy 16.16 14.69 3 26144 77996 79640245
Wound 16.12 14.69 9 26138 116170 79602071
Injection site warmth 16.10 14.69 22 26125 14785 79703456
Muscle disorder 16.05 14.69 14 26133 5693 79712548
Thyroid neoplasm 16.01 14.69 11 26136 3153 79715088
Visual acuity reduced 15.99 14.69 32 26115 29437 79688804
Cough 15.95 14.69 64 26083 366725 79351516
Peripheral swelling 15.95 14.69 41 26106 269576 79448665
Drug hypersensitivity 15.79 14.69 48 26099 298868 79419373
Caesarean section 15.76 14.69 20 26127 12515 79705726
Bladder disorder 15.47 14.69 17 26130 9148 79709093
Injection site abscess sterile 15.38 14.69 3 26144 17 79718224
Automatic bladder 15.21 14.69 4 26143 97 79718144
Oxygen saturation decreased 15.21 14.69 12 26135 129035 79589206
Sepsis 15.15 14.69 42 26105 269386 79448855
Dizziness 14.96 14.69 249 25898 526192 79192049
Skin discolouration 14.92 14.69 38 26109 40996 79677245
Osteoarthritis 14.91 14.69 5 26142 87304 79630937
Cellulitis 14.88 14.69 73 26074 108987 79609254
Injection site exfoliation 14.82 14.69 5 26142 290 79717951

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AB08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025715 Interferon-beta
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D007155 Immunologic Factors
FDA EPC N0000191625 Interferon beta

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
TTD90R31WZ UNII
4023900 VANDF
C0244713 UMLSCUI
CHEBI:5938 CHEBI
CHEMBL1201563 ChEMBL_ID
D00746 KEGG_DRUG
DB00068 DRUGBANK_ID
D000068576 MESH_DESCRIPTOR_UI
72257 RXNORM
304 MMSL
4896 MMSL
d03051 MMSL
004370 NDDF
108751004 SNOMEDCT_US
386903009 SNOMEDCT_US

Pharmaceutical products:

None